Choueiri, Toni K <br/><br/>
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.  [electronic resource] 

 -  The Journal of urology  Sep 2008 
 - 860-5; discussion 865-6 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1527-3792 
<br/><br/><label>Standard No.: </label>10.1016/j.juro.2008.05.015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--therapeutic use<br/>Axitinib<br/>Benzenesulfonates--therapeutic use<br/>Bevacizumab<br/>Carcinoma, Renal Cell--drug therapy<br/>Chi-Square Distribution<br/>DNA Primers<br/>Female<br/>Humans<br/>Imidazoles--therapeutic use<br/>Indazoles--therapeutic use<br/>Indoles--therapeutic use<br/>Kidney Neoplasms--drug therapy<br/>Logistic Models<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Neoplasm Metastasis<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Prognosis<br/>Pyridines--therapeutic use<br/>Pyrroles--therapeutic use<br/>Sorafenib<br/>Sunitinib<br/>Survival Rate<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>von Hippel-Lindau Disease--genetics